Related Experiment Video
Updated: May 12, 2026
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Myasthenia gravis and pregnancy
1Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA. michael.varner@hsc.utah.edu
Clinical Obstetrics and Gynecology
|April 9, 2013
Summary
Myasthenia gravis, an autoimmune neuromuscular junction disease, presents with fluctuating muscle weakness. Pregnancy impacts vary, with potential exacerbations and risks to newborns from antibody exposure.
Area of Science:
- Neurology
- Immunology
- Obstetrics
Background:
- Myasthenia gravis is an autoimmune disorder affecting the neuromuscular junction, causing skeletal muscle weakness.
- Pregnancy can influence myasthenia gravis, with exacerbations often occurring in the first trimester or postpartum period.
- Certain medications used in obstetrics may worsen myasthenia gravis symptoms.
Purpose of the Study:
- To review the impact of pregnancy on myasthenia gravis.
- To highlight potential risks and management strategies during pregnancy.
- To inform obstetric practice regarding myasthenia gravis management.
Main Methods:
- Literature review of myasthenia gravis in pregnancy.
- Analysis of disease course variations during gestation.
- Summary of current treatment modalities.
- Assessment of neonatal outcomes related to maternal myasthenia gravis.
Main Results:
- The effect of pregnancy on myasthenia gravis is highly individualized, varying between women and pregnancies.
- Exacerbations are more common during early pregnancy and the puerperium.
- Neonatal complications, typically transient, can arise from transplacental antibody transfer.
Conclusions:
- Management requires a multidisciplinary approach, including acetylcholine esterase inhibitors, immunosuppressants, and rest.
- Careful consideration of obstetric medications is crucial to avoid exacerbating myasthenia gravis.
- Transient neonatal effects necessitate monitoring of newborns exposed to maternal antibodies.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...